Free Trial
NASDAQ:CELU

Celularity Q4 2025 Earnings Results & Report

Celularity logo
$0.61 -0.02 (-2.71%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Celularity reported Q4 2025 earnings on April 30, 2026. The company reported EPS of -$0.85, while revenue was $4.10 million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Celularity EPS Results

Actual EPS
-$0.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 6 quarters

Celularity Revenue Results

Actual Revenue
$4.10 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Celularity Q4 2025 Earnings FAQ

Celularity (NASDAQ:CELU) reported earnings of -$0.85 per share for Q4 2025. The report was announced on Thursday, April 30, 2026.

Celularity reported revenue of $4.10 million for Q4 2025.

Celularity Earnings Headlines

A Nasdaq drone company just landed a deal with a Philippine billionaire's group
A Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billionaire Enrique Razon Jr.'s business empire. The Razon Group spans ports, energy, mining, utilities and infrastructure, and its affiliated port operator generated over $3.2 billion in 2025 revenue. The deal lays the groundwork for drone manufacturing in the Philippines, with potential expansion across Southeast Asia. The company was also selected for a five-year Canadian Armed Forces contract covering 100 systems, with options for up to 4,900 more. It supplies the U.S. Army, holds a U.S. Air Force Special Operations Command contract, and recently announced a $10 million strategic investment from Unusual Machines.tc pixel
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease.

The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. Its work focuses on developing and manufacturing placenta-derived products for clinical and commercial use.

View Celularity Profile